Cargando…

Pharmacokinetic modeling of a novel hypoxia PET tracer [(18)F]HX4 in patients with non-small cell lung cancer

BACKGROUND: [(18)F]HX4 is a promising new PET tracer developed to identify hypoxic areas in tumor tissue. This study analyzes [(18)F]HX4 kinetics and assesses the performance of simplified methods for quantification of [(18)F]HX4 uptake. To this end, eight patients with non-small cell lung cancer re...

Descripción completa

Detalles Bibliográficos
Autores principales: Verwer, E. E., Zegers, C. M. L., van Elmpt, W., Wierts, R., Windhorst, A. D., Mottaghy, F. M., Lambin, P., Boellaard, R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5153396/
https://www.ncbi.nlm.nih.gov/pubmed/27957730
http://dx.doi.org/10.1186/s40658-016-0167-y
_version_ 1782474681695076352
author Verwer, E. E.
Zegers, C. M. L.
van Elmpt, W.
Wierts, R.
Windhorst, A. D.
Mottaghy, F. M.
Lambin, P.
Boellaard, R.
author_facet Verwer, E. E.
Zegers, C. M. L.
van Elmpt, W.
Wierts, R.
Windhorst, A. D.
Mottaghy, F. M.
Lambin, P.
Boellaard, R.
author_sort Verwer, E. E.
collection PubMed
description BACKGROUND: [(18)F]HX4 is a promising new PET tracer developed to identify hypoxic areas in tumor tissue. This study analyzes [(18)F]HX4 kinetics and assesses the performance of simplified methods for quantification of [(18)F]HX4 uptake. To this end, eight patients with non-small cell lung cancer received dynamic PET scans at three different time points (0, 120, and 240 min) after injection of 426 ± 72 MBq [(18)F]HX4, each lasting 30 min. Several compartment models were fitted to time activity curves (TAC) derived from various areas within tumor tissue using image-derived input functions. RESULTS: Best fits were obtained using the reversible two-tissue compartment model with blood volume parameter (2T4k+V(B)). Simplified measures correlated well with V(T) estimates (tumor-to-blood ratio (TBr) R (2) = 0.96, tumor-to-muscle ratio R (2) = 0.94, standardized uptake value R (2) = 0.89). CONCLUSIONS: [(18)F]HX4 shows reversible kinetics in tumor tissue: 2T4k+V(B). TBr based on static imaging at 2 or 4 h can be used for quantification of [(18)F]HX4 uptake. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s40658-016-0167-y) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5153396
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-51533962016-12-27 Pharmacokinetic modeling of a novel hypoxia PET tracer [(18)F]HX4 in patients with non-small cell lung cancer Verwer, E. E. Zegers, C. M. L. van Elmpt, W. Wierts, R. Windhorst, A. D. Mottaghy, F. M. Lambin, P. Boellaard, R. EJNMMI Phys Original Research BACKGROUND: [(18)F]HX4 is a promising new PET tracer developed to identify hypoxic areas in tumor tissue. This study analyzes [(18)F]HX4 kinetics and assesses the performance of simplified methods for quantification of [(18)F]HX4 uptake. To this end, eight patients with non-small cell lung cancer received dynamic PET scans at three different time points (0, 120, and 240 min) after injection of 426 ± 72 MBq [(18)F]HX4, each lasting 30 min. Several compartment models were fitted to time activity curves (TAC) derived from various areas within tumor tissue using image-derived input functions. RESULTS: Best fits were obtained using the reversible two-tissue compartment model with blood volume parameter (2T4k+V(B)). Simplified measures correlated well with V(T) estimates (tumor-to-blood ratio (TBr) R (2) = 0.96, tumor-to-muscle ratio R (2) = 0.94, standardized uptake value R (2) = 0.89). CONCLUSIONS: [(18)F]HX4 shows reversible kinetics in tumor tissue: 2T4k+V(B). TBr based on static imaging at 2 or 4 h can be used for quantification of [(18)F]HX4 uptake. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s40658-016-0167-y) contains supplementary material, which is available to authorized users. Springer International Publishing 2016-12-12 /pmc/articles/PMC5153396/ /pubmed/27957730 http://dx.doi.org/10.1186/s40658-016-0167-y Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Research
Verwer, E. E.
Zegers, C. M. L.
van Elmpt, W.
Wierts, R.
Windhorst, A. D.
Mottaghy, F. M.
Lambin, P.
Boellaard, R.
Pharmacokinetic modeling of a novel hypoxia PET tracer [(18)F]HX4 in patients with non-small cell lung cancer
title Pharmacokinetic modeling of a novel hypoxia PET tracer [(18)F]HX4 in patients with non-small cell lung cancer
title_full Pharmacokinetic modeling of a novel hypoxia PET tracer [(18)F]HX4 in patients with non-small cell lung cancer
title_fullStr Pharmacokinetic modeling of a novel hypoxia PET tracer [(18)F]HX4 in patients with non-small cell lung cancer
title_full_unstemmed Pharmacokinetic modeling of a novel hypoxia PET tracer [(18)F]HX4 in patients with non-small cell lung cancer
title_short Pharmacokinetic modeling of a novel hypoxia PET tracer [(18)F]HX4 in patients with non-small cell lung cancer
title_sort pharmacokinetic modeling of a novel hypoxia pet tracer [(18)f]hx4 in patients with non-small cell lung cancer
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5153396/
https://www.ncbi.nlm.nih.gov/pubmed/27957730
http://dx.doi.org/10.1186/s40658-016-0167-y
work_keys_str_mv AT verweree pharmacokineticmodelingofanovelhypoxiapettracer18fhx4inpatientswithnonsmallcelllungcancer
AT zegerscml pharmacokineticmodelingofanovelhypoxiapettracer18fhx4inpatientswithnonsmallcelllungcancer
AT vanelmptw pharmacokineticmodelingofanovelhypoxiapettracer18fhx4inpatientswithnonsmallcelllungcancer
AT wiertsr pharmacokineticmodelingofanovelhypoxiapettracer18fhx4inpatientswithnonsmallcelllungcancer
AT windhorstad pharmacokineticmodelingofanovelhypoxiapettracer18fhx4inpatientswithnonsmallcelllungcancer
AT mottaghyfm pharmacokineticmodelingofanovelhypoxiapettracer18fhx4inpatientswithnonsmallcelllungcancer
AT lambinp pharmacokineticmodelingofanovelhypoxiapettracer18fhx4inpatientswithnonsmallcelllungcancer
AT boellaardr pharmacokineticmodelingofanovelhypoxiapettracer18fhx4inpatientswithnonsmallcelllungcancer